spinraza
medison pharma ltd - nusinersen - solution for injection - nusinersen 2.4 mg / 1 ml - spinraza is indicated for the treatment of 5q spinal muscular atrophy except type 0 and type iv.
spinraza
medison pharma ltd - nusinersen - solution for injection - nusinersen 2.4 mg / 1 ml - spinraza is indicated for the treatment of 5q spinal muscular atrophy except type 0 and type iv.
spinraza 2.4 mg/ml vial solution for injection
biogen idec ltd, united kingdom - nusinersen - solution for injection - 12 mg
spinraza 2.4 mg/ml vial solution for injection
biogen idec b.v-natherland, netherlands - nusinersen - solution for injection - 12 mg
evrysdi
roche products (nz) ltd - risdiplam 0.75 mg/ml - powder for oral solution - 750 mcg/ml - active: risdiplam 0.75 mg/ml excipient: ascorbic acid disodium edetate dihydrate isomalt macrogol 600 mannitol sodium benzoate strawberry flavour phs-180152 sucralose tartaric acid - evrysdi is indicated for the treatment of spinal muscular atrophy (sma) in patients aged 2 months and older.
evrysdi
roche registration gmbh - risdiplam - muscular atrophy, spinal - other drugs for disorders of the musculo-skeletal system - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.
evrysdi powder for solution
hoffmann-la roche limited - risdiplam - powder for solution - 0.75mg - risdiplam 0.75mg - other miscellaneous therapeutic agents
evrysdi powder for oral solution 0.75 mgml
roche singapore pte. ltd. - risdiplam - powder, for solution - risdiplam 60 mg
evrysdi
roche pharmaceuticals (israel) ltd - risdiplam - powder for solution - risdiplam 60 mg/bottle - risdiplam - evrysdi is indicated for the treatment of spinal muscular atrophy (sma) types 1,2 and 3 in patients 2 months of age and older.
spinraza 12 mg solució injectable 1 vial 5 ml